Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...

Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...